



STANDARDIZED ONE PAGE PHARMACY PRIOR AUTHORIZATION FORM

Mississippi Division of Medicaid, Pharmacy Prior Authorization Unit,
Gainwell Technologies, PO Box 2480, Ridgeland, MS 39158

Medicaid Fee for Service/MSCAN/MSCHIP Members
Gainwell Technologies

Fax to: 1-866-644-6147 Ph: 1-833-660-2402

[Pharmacy Prior Authorization - Mississippi Division of Medicaid \(ms.gov\)](https://ms-medicaid-mesa.com)

Submit your PA requests via the MESA (Medicaid Enterprise System Assistance) provider portal for the most efficient processing
[Mississippi Medical Assistance Portal for Providers > Home \(ms-medicaid-mesa.com\)](https://ms-medicaid-mesa.com)

BENEFICIARY INFORMATION	
Beneficiary ID: _____ - _____ - _____	DOB: ____/____/____
Beneficiary Full Name: _____	
PRESCRIBER INFORMATION	
Prescriber's NPI: _____	
Prescriber's Full Name: _____	Phone: _____
Prescriber's Address: _____	FAX: _____
PHARMACY INFORMATION	
Pharmacy NPI: _____	
Pharmacy Name: _____	
Pharmacy Phone: _____	Pharmacy FAX: _____
CLINICAL INFORMATION	
Requested PA Start Date: _____ Requested PA End Date: _____	
Drug/Product Requested: _____ Strength: _____ Quantity: _____	
Days Supply: _____ RX Refills: _____ Diagnosis or ICD-10 Code(s): _____	
☐ Hospital Discharge ☐ Additional Medical Justification Attached	
Medications received through coupons and/or samples are not acceptable as justification.	
PLEASE COMPLETE AND FAX DRUG SPECIFIC CRITERIA/ADDITIONAL DOCUMENTATION FORM FOUND BELOW	
Prescribing provider's signature (signature and date stamps, or the signature of anyone other than the provider, are not acceptable)	
I certify that all information provided is accurate and appropriately documented in the patient's medical chart.	
Signature required: _____ Date: _____	
Printed name of prescribing provider: _____	

FAX THIS PAGE



Prior Authorization Criteria

Select Covered Obesity Medications PA Criteria

While there are various medications with differing mechanisms of action that are FDA-approved to treat obesity, Mississippi Medicaid covers select agents for this condition. Coverage, subject to prior authorization, is outlined below.

Preferred: Saxenda or Wegovy for ages 12 and older

Non-Preferred: Xenical or orlistat for ages 12 and older

The following agents are not covered by Mississippi Medicaid:

Contrave – *This agent is not rebated through CMS.*

Qsymia – *This agent is not rebated through CMS.*

Phentermine, Evekeo/amphetamine – *These agents have not been shown to produce longer-term health benefits in patients who are obese or overweight.*

Coverage of select medications for the treatment of obesity will be limited to only one covered product at a given time. Mississippi Medicaid will not cover concurrent use of two or more agents for the treatment of obesity.

Mississippi Medicaid does not cover medications for treatment of obesity during pregnancy or for mothers who are breast-feeding.

Note: Saxenda and Wegovy are GLP-1 agonists and should be avoided in patients with multiple endocrine neoplasia syndrome type 2 or a personal or family history of medullary thyroid carcinoma. These agents are contraindicated for concomitant use with other GLP-1 agonists or DPP-4 inhibitors.

HELPFUL RESOURCES:

1. BMI Calculator: <https://www.nhlbi.nih.gov/calculate-your-bmi>
2. BMI Chart: https://www.nhlbi.nih.gov/sites/default/files/media/docs/bmi_tbl.pdf
3. CDC Growth Charts: <https://www.cdc.gov/growthcharts/cdc-growth-charts.htm>
4. CDC Extended BMI for Age Growth Charts: <https://www.cdc.gov/growthcharts/Extended-BMI-Charts.html>

The following criteria encompasses 3 phases of medication treatment of obesity:

- Initial authorization – Patient is evaluated for initiation of treatment. Patient must qualify for treatment based on BMI and/or BMI and other health conditions. A treatment plan is designed by the provider during this phase.
- Reauthorization – Patient is evaluated for continuation of treatment. During this phase, the patient is making progress toward overcoming obesity and/or weight-related comorbidities.
- Maintenance – Patient has reached their goal BMI and treatment shifts toward maintaining the progress they have made.

Provider Information and Point of Contact:

Prescribing Provider's Medicaid ID: _____

Office Contact Name: _____ Phone: _____ Ext. _____

I. Initial Authorization:

Duration: Saxenda, Wegovy: 6 months

A. Adults (18 year or older) – Saxenda or Wegovy

- ☐ BMI 30 or greater
- ☐ BMI 25 to 29 for Wegovy **OR** BMI 27 to 29 for Saxenda with at least one weight-related comorbidity:
- ☐ Hypertension – Confirmed by claims history of antihypertensive medication.
- ☐ Hyperlipidemia – Confirmed by:
- ☐ Claims history of antihyperlipidemic medication, OR
 - ☐ If no medication history, lipid levels: Date of panel _____
Total Chol. _____ LDL _____ HDL _____ TG _____
- ☐ Glucose dysregulation – Confirmed by:
- ☐ Diabetes with history of glucose lowering medication OR
 - ☐ Pre-diabetes. Defined as:
 - Δ Fasting glucose ≥ 100 , Value _____ Date _____, OR
 - Δ 2-hour OGTT ≥ 140 , Value _____ Date _____, OR
 - Δ HbA1C $\geq 5.7\%$, Value _____ Date _____
- ☐ Obstructive sleep apnea – Confirmed by prior sleep study.
- ☐ Cardiovascular disease – coronary artery disease, heart failure, prior MI or CVA
- ☐ Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)]
- ☐ Other _____
(attach detailed clinical justification)

B. Children (age 12 - 17 years) – Saxenda or Wegovy

Saxenda:

- ☐ Body weight above 60 kg, AND
- ☐ Initial BMI corresponding to 30 or greater for adults by international cut-offs

Wegovy:

- ☐ BMI at $\geq 95^{\text{th}}$ percentile for age and sex (see chart below)

Age (years)	BMI at 95% percentile		Age (years)	BMI at 95% percentile	
	Male	Female		Male	Female
12	24.2	25.2	15	26.8	28.1
12.5	24.7	25.7	15.5	27.2	28.5
13	25.1	26.3	16	27.5	28.9
13.5	25.3	26.8	16.5	27.9	29.3
14	26	27.2	17	28.2	29.6
14.5	26.4	27.7	17.5	28.6	30

*See above CDC link for BMI reference, i.e., z-scores and percentiles, for children.

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-833-660-2402) or fax (1-866-644-6147) and destroy all copies of the original message. 10/30/2025

****REQUIRED FOR ALL PATIENTS:****Treatment Plan for Qualified Beneficiaries**

Patient current BMI: _____

Patient current weight: _____ height: _____

6 Month treatment goal BMI/weight: _____

Other non-scale treatment goals: _____

Treatment Plan Expected Duration: _____

☐ Yes, ☐ No Has the patient been counseled on appropriate dietary choices and increasing physical activity appropriate to the patient's ability?

☐ Yes, ☐ No Is the obesity treatment plan attached to this form as required?

II. Reauthorization – This phase encompasses the second authorization period.

Patient age: _____

Patient BMI at initial authorization: _____ Date of BMI at initial authorization: _____

Patient current BMI: _____ (If at goal or BMI < 25, see III. Maintenance below)

Patient weight at initial authorization: _____ Date of weight at initial authorization: _____

Patient current weight: _____ height: _____

Did the patient reach the initial authorization treatment plan goal? ☐ Yes ☐ No

If no, provide clinical justification for continuation of current therapy. _____

Next 6 month treatment plan goals: _____

☐ Yes, ☐ No Has the patient been counseled on appropriate dietary choices and increasing physical activity appropriate to the patient's ability?

Reauthorization to continue treatment is subject to the following:

☐ Yes, ☐ No Has patient been adherent, as evidenced in paid pharmacy claims?
Adherence is defined as 3 claims in the past 105 days.

(see next page for additional questions)

☐ Yes, ☐ No Is the member tolerating the recommended target dose of 3 mg daily for Saxenda OR 1.7 mg or 2.4 mg weekly for Wegovy?

- ☐ Weight loss 5% or greater – Approve for additional 6 months.
- ☐ Weight loss 1-4% - May be approved 3 months if one of the following applies:
- ☐ Titration schedule was delayed due to intolerance.
 - ☐ Titration was delayed by hospitalization or illness as documented by evidence of treatment in claims history.
 - ☐ Other non-scale treatment goal progress:

- ☐ 3 month treatment goal if approved:

- ☐ Weight loss less than 1% - Deny reauthorization. Consider another covered agent.

III. Maintenance Reauthorization – 6 months

Patient age: _____

Patient BMI at initial authorization: _____ Date of BMI at initial authorization: _____

Patient current BMI: _____

Patient weight at initial authorization: _____ Date of weight at initial authorization: _____

Patient current weight: _____ height: _____

Did the patient reach the treatment plan goal from last PA approval? ☐ Yes ☐ No

If no, provide clinical justification for continuation of current therapy. _____

Next 6-month treatment plan goals: _____

☐ Yes, ☐ No Has the patient been counseled on appropriate dietary choices and increasing physical activity appropriate to the patient's ability?

☐ Yes, ☐ No Has patient been adherent, as evidenced in paid pharmacy claims? Adherence is defined as 3 claims in the past 105 days.

☐ Yes, ☐ No Is the member tolerating the recommended target dose of 3 mg daily for Saxenda OR 1.7 mg or 2.4 mg weekly for Wegovy?

☐ Yes, ☐ No Once goal BMI is achieved, has the member maintained a body weight within 15% of goal BMI.